Sample · Decode
See your pain & anesthesia results in Decode
A real preview of how your genetic variants affect pain medications and anesthesia response — personalized to your genetics.
Free to start · $59 one-time, lifetime access
What you'll see inside Decode
Decode analyzes 4 genes across pain sensitivity and opioid response — plus an honest answer on CYP2D6, the gene behind codeine and tramadol metabolism.
Summary Snapshot
A quick overview of how many actionable scenarios were identified, genes analyzed, and what to do next.
What We See in Your Data
A plain-language synthesis connecting your genetic variants to real-world pain and anesthesia implications.
Scenario Cards
Each scenario explains a specific clinical situation — what it means, which genes are involved, and what to discuss with your provider.
Medications Table
Pain and anesthesia medications mapped to your genetic results with action flags and clinical reasoning.
Limitations & Disclaimers
Transparent disclosure of what your results can and cannot tell you, including gene coverage and evidence level.
Your pain & anesthesia results — full sample
Sample Data — Not Your Results
Your Pain & Anesthesia Results
Inside Decode — sample preview
Based on pharmacogenomic research for pain management and anesthesia
Summary Snapshot
Multiple Actionable FindingsYour genetics suggest several important considerations for pain management and anesthesia. Multiple variants affect how you process pain signals and metabolize common pain medications.
Do this next: Share your results with your pain specialist or anesthesiologist before any procedure or new pain medication.
What We See in Your Data
Your OPRM1 variant (A/G at rs1799971) is associated with reduced opioid receptor binding, which may mean standard opioid doses provide less analgesic effect. Combined with your COMT result (Met/Met at rs4680), which is linked to lower pain thresholds and higher pain sensitivity, your overall pain management profile suggests a need for careful medication selection and dose adjustment. Your BDNF variant (Val/Met) and ANKK1 variant further contribute to how you experience and recover from pain. Codeine and tramadol both rely on CYP2D6 to convert into their active forms — but CYP2D6 needs a specialized caller that a consumer DNA array does not provide. Rather than guess at a result, Decode tells you this honestly and points you to CPIC guidance and clinical CYP2D6 testing for codeine- and tramadol-related decisions.
Your Scenarios
Codeine and tramadol depend on CYP2D6 — but CYP2D6 needs a specialized caller that a consumer DNA array does not provide.
Genes Involved
CYP2D6 Not callable from array data — Requires specialized testing
CYP2D6 converts codeine to morphine and tramadol to its active metabolite O-desmethyltramadol, and CPIC guidelines are built around CYP2D6 metabolizer status for these drugs. But CYP2D6 has structural and copy-number variation — gene deletions and duplications — that consumer genotyping arrays cannot resolve reliably. Rather than guess, we tell you the truth: we will never invent a CYP2D6 result it cannot support.
Recommendations
- If you need to know your CYP2D6 status for codeine or tramadol decisions, ask your provider about clinical CYP2D6 testing — a buccal swab or blood-based test, not consumer array genotyping.
- CPIC guidelines for codeine and CYP2D6 remain clinically relevant — raise them with your prescriber regardless of testing method.
- Decode does analyze OPRM1, COMT, BDNF, and ANKK1 from your data — see the scenarios below for what we can tell you about those.
References: CPIC Codeine Guideline 2020, PharmCAT CYP2D6 calling limitations
Your opioid receptor variant is associated with reduced binding affinity and lower analgesic response.
Full scenario with genes involved, explanation, and recommendations in Decode
Your COMT variant is associated with lower enzyme activity and heightened pain sensitivity.
Full scenario with genes involved, explanation, and recommendations in Decode
A BDNF variant contributes to differences in how pain signals are transmitted and modulated.
Full scenario with genes involved, explanation, and recommendations in Decode
An ANKK1/DRD2 variant affects dopamine receptor density, influencing pain recovery and reward processing.
Full scenario with genes involved, explanation, and recommendations in Decode
4 additional scenarios with full explanations, gene details, and recommendations in Decode
Pain & Anesthesia Medications
| Medication | Category | Status | Reason |
|---|---|---|---|
| codeine (Tylenol #3) | Opioid Analgesic | Review | Relies on CYP2D6 to activate — Decode cannot call CYP2D6 from array data, so this cannot be resolved from your results |
| tramadol (Ultram) | Opioid Analgesic | Review | Relies on CYP2D6 to activate — Decode cannot call CYP2D6 from array data, so this cannot be resolved from your results |
| hydrocodone (Vicodin) | Opioid Analgesic | Review | Relies on CYP2D6 to activate — Decode cannot call CYP2D6 from array data, so this cannot be resolved from your results |
| morphine (MS Contin) | Opioid Analgesic | OPRM1 A/G — may require higher doses for adequate analgesia |
| oxycodone (OxyContin) | Opioid Analgesic | OPRM1 A/G — altered receptor binding may reduce efficacy |
+11 more medications checked in Decode
Limitations & Disclaimers
- Decode evaluates OPRM1, COMT, BDNF, and ANKK1 for pain. CYP2D6 also matters for codeine and tramadol response, but it needs a specialized caller that a consumer array does not provide — Decode flags this honestly rather than guess at a result. Other genes influencing pain response (e.g., SCN9A, ABCB1, CYP3A4) are not included.
- Genotyping from consumer DNA kits may not capture all star alleles or structural variants. Clinical-grade testing may identify additional variants.
- Pain is multifactorial — genetics is one component alongside psychological, environmental, and contextual factors.
- CPIC's opioid guideline examined OPRM1 and COMT and made no dosing recommendation for either, judging the evidence insufficient. BDNF and ANKK1 findings are research-level and are not covered by a CPIC guideline.
- Medication decisions should always be made with a qualified healthcare provider who can consider your complete clinical picture.
- Decode does not account for drug-drug interactions, organ function, or other clinical variables that affect medication response.
This is a sample built from fictional data for demonstration purposes. Your own results in Decode reflect your personal genetics.
Decode your own pain & anesthesia response
Upload your 23andMe or AncestryDNA raw data. See your genome overview free; unlock your pain & anesthesia results with a one-time $59 — yours for life.
Get Started FreeFree vs Decode
Create your account and see your genome overview free. Decode maps your variants to specific pain medications and anesthesia considerations.
Free to start
- Create your account & upload 23andMe or AncestryDNA
- Your genome overview — genes analyzed, variants found
- Delete your data anytime (export via support)
- Which pain medications are affected
- Pain sensitivity and opioid response scenarios
- Anesthesia-specific recommendations
Decode
$59 one-time- Everything in free, plus:
- 4 genes analyzed across pain and anesthesia pathways
- Scenario-based findings with clinical context
- 14 pain medications mapped to your genetic results
- Opioid response and sensitivity profile
- Plus medications, carrier status, nutrition, ancestry & the AI assistant
Pain Pharmacogenomics from DNA You Already Have
Clinical pain PGx testing costs $300+ and requires a new sample, a prescription, and often insurance pre-authorization. Decode uses raw data from 23andMe or AncestryDNA — data you already have — free to start, then a one-time $59 you own for life.
Both approaches reference the same pharmacogenomic research for opioid metabolism and pain sensitivity. The difference: you already have the data.
Built on Pharmacogenomic Evidence
OPRM1, COMT, BDNF, and ANKK1 findings are based on peer-reviewed pharmacogenomic research with consistent replication across multiple studies. CYP2D6's role in codeine and tramadol response is backed by CPIC clinical guidelines — but CYP2D6 can't be reliably called from a consumer array, so Decode explains the science honestly rather than report a CYP2D6 finding it can't support.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Ready to See Your Pain & Anesthesia Results?
Upload your 23andMe or AncestryDNA raw data and read your results inside Decode. Free to start — then $59 one-time, yours for life.